Gliomatosis cerebri

Clinical characteristics, management, and outcomes

Selby Chen, Shota Tanaka, Caterina Giannini, Jonathan Morris, Elizabeth S. Yan, Jan Craig Buckner, Daniel H Lachance, Ian F Parney

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Gliomatosis cerebri is a rare diffusely infiltrating primary neoplastic glial process of the brain. Our objective is to review clinical presentation, management, and outcome in a large single institution series of gliomatosis cerebri patients. 54 consecutive gliomatosis cerebri cases presenting to Mayo Clinic Rochester between 1991 and 2008 were retrospectively reviewed. Inclusion criteria included involvement of at least three cerebral lobes, lack of a single discrete mass and pathological confirmation of diffuse glioma. Median overall survival (OS) was 18.5 months. Age, gender, presenting symptoms, and contrast enhancement did not correlate significantly with survival, though there was a trend toward decreased overall survival in patients above the median age of 46 years. Karnofsky performance score <70 was associated with poor OS (median 9.5 vs. 20.5 months, p = 0.02). Higher histologic grade was associated with poor progression-free survival (PFS; median for WHO grades II, III, and IV: 21.5, 6.5, and 4 months; p = 0.03) and OS (median 34, 15.5, and 8.5 months; p < 0.05). Radiation therapy was strongly associated with better prognosis (PFS 16.5 vs. 4.5 months, p < 0.01; OS 27.5 vs. 6.5, p < 0.01), but chemotherapy was not. Gliomatosis cerebri patients have a poor prognosis. Lower KPS upon presentation and higher histologic grade predict decreased survival. Surgery's role is limited beyond biopsy for diagnostic purposes. Radiotherapy appears beneficial, although selection bias could be present in this retrospective study. Chemotherapy's value is not as clear but this must be interpreted with caution given variable treatment regimens in this series.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalJournal of Neuro-Oncology
Volume112
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Neuroepithelial Neoplasms
Survival
Radiotherapy
Neoplastic Processes
Drug Therapy
Selection Bias
Glioma
Neuroglia
Disease-Free Survival
Retrospective Studies
Biopsy
Brain

Keywords

  • Chemotherapy
  • Gliomatosis cerebri
  • Malignant glioma
  • Radiation
  • Surgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Gliomatosis cerebri : Clinical characteristics, management, and outcomes. / Chen, Selby; Tanaka, Shota; Giannini, Caterina; Morris, Jonathan; Yan, Elizabeth S.; Buckner, Jan Craig; Lachance, Daniel H; Parney, Ian F.

In: Journal of Neuro-Oncology, Vol. 112, No. 2, 04.2013, p. 267-275.

Research output: Contribution to journalArticle

@article{36b282ff8ff34333bf80c8fa4fcb421c,
title = "Gliomatosis cerebri: Clinical characteristics, management, and outcomes",
abstract = "Gliomatosis cerebri is a rare diffusely infiltrating primary neoplastic glial process of the brain. Our objective is to review clinical presentation, management, and outcome in a large single institution series of gliomatosis cerebri patients. 54 consecutive gliomatosis cerebri cases presenting to Mayo Clinic Rochester between 1991 and 2008 were retrospectively reviewed. Inclusion criteria included involvement of at least three cerebral lobes, lack of a single discrete mass and pathological confirmation of diffuse glioma. Median overall survival (OS) was 18.5 months. Age, gender, presenting symptoms, and contrast enhancement did not correlate significantly with survival, though there was a trend toward decreased overall survival in patients above the median age of 46 years. Karnofsky performance score <70 was associated with poor OS (median 9.5 vs. 20.5 months, p = 0.02). Higher histologic grade was associated with poor progression-free survival (PFS; median for WHO grades II, III, and IV: 21.5, 6.5, and 4 months; p = 0.03) and OS (median 34, 15.5, and 8.5 months; p < 0.05). Radiation therapy was strongly associated with better prognosis (PFS 16.5 vs. 4.5 months, p < 0.01; OS 27.5 vs. 6.5, p < 0.01), but chemotherapy was not. Gliomatosis cerebri patients have a poor prognosis. Lower KPS upon presentation and higher histologic grade predict decreased survival. Surgery's role is limited beyond biopsy for diagnostic purposes. Radiotherapy appears beneficial, although selection bias could be present in this retrospective study. Chemotherapy's value is not as clear but this must be interpreted with caution given variable treatment regimens in this series.",
keywords = "Chemotherapy, Gliomatosis cerebri, Malignant glioma, Radiation, Surgery",
author = "Selby Chen and Shota Tanaka and Caterina Giannini and Jonathan Morris and Yan, {Elizabeth S.} and Buckner, {Jan Craig} and Lachance, {Daniel H} and Parney, {Ian F}",
year = "2013",
month = "4",
doi = "10.1007/s11060-013-1058-x",
language = "English (US)",
volume = "112",
pages = "267--275",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Gliomatosis cerebri

T2 - Clinical characteristics, management, and outcomes

AU - Chen, Selby

AU - Tanaka, Shota

AU - Giannini, Caterina

AU - Morris, Jonathan

AU - Yan, Elizabeth S.

AU - Buckner, Jan Craig

AU - Lachance, Daniel H

AU - Parney, Ian F

PY - 2013/4

Y1 - 2013/4

N2 - Gliomatosis cerebri is a rare diffusely infiltrating primary neoplastic glial process of the brain. Our objective is to review clinical presentation, management, and outcome in a large single institution series of gliomatosis cerebri patients. 54 consecutive gliomatosis cerebri cases presenting to Mayo Clinic Rochester between 1991 and 2008 were retrospectively reviewed. Inclusion criteria included involvement of at least three cerebral lobes, lack of a single discrete mass and pathological confirmation of diffuse glioma. Median overall survival (OS) was 18.5 months. Age, gender, presenting symptoms, and contrast enhancement did not correlate significantly with survival, though there was a trend toward decreased overall survival in patients above the median age of 46 years. Karnofsky performance score <70 was associated with poor OS (median 9.5 vs. 20.5 months, p = 0.02). Higher histologic grade was associated with poor progression-free survival (PFS; median for WHO grades II, III, and IV: 21.5, 6.5, and 4 months; p = 0.03) and OS (median 34, 15.5, and 8.5 months; p < 0.05). Radiation therapy was strongly associated with better prognosis (PFS 16.5 vs. 4.5 months, p < 0.01; OS 27.5 vs. 6.5, p < 0.01), but chemotherapy was not. Gliomatosis cerebri patients have a poor prognosis. Lower KPS upon presentation and higher histologic grade predict decreased survival. Surgery's role is limited beyond biopsy for diagnostic purposes. Radiotherapy appears beneficial, although selection bias could be present in this retrospective study. Chemotherapy's value is not as clear but this must be interpreted with caution given variable treatment regimens in this series.

AB - Gliomatosis cerebri is a rare diffusely infiltrating primary neoplastic glial process of the brain. Our objective is to review clinical presentation, management, and outcome in a large single institution series of gliomatosis cerebri patients. 54 consecutive gliomatosis cerebri cases presenting to Mayo Clinic Rochester between 1991 and 2008 were retrospectively reviewed. Inclusion criteria included involvement of at least three cerebral lobes, lack of a single discrete mass and pathological confirmation of diffuse glioma. Median overall survival (OS) was 18.5 months. Age, gender, presenting symptoms, and contrast enhancement did not correlate significantly with survival, though there was a trend toward decreased overall survival in patients above the median age of 46 years. Karnofsky performance score <70 was associated with poor OS (median 9.5 vs. 20.5 months, p = 0.02). Higher histologic grade was associated with poor progression-free survival (PFS; median for WHO grades II, III, and IV: 21.5, 6.5, and 4 months; p = 0.03) and OS (median 34, 15.5, and 8.5 months; p < 0.05). Radiation therapy was strongly associated with better prognosis (PFS 16.5 vs. 4.5 months, p < 0.01; OS 27.5 vs. 6.5, p < 0.01), but chemotherapy was not. Gliomatosis cerebri patients have a poor prognosis. Lower KPS upon presentation and higher histologic grade predict decreased survival. Surgery's role is limited beyond biopsy for diagnostic purposes. Radiotherapy appears beneficial, although selection bias could be present in this retrospective study. Chemotherapy's value is not as clear but this must be interpreted with caution given variable treatment regimens in this series.

KW - Chemotherapy

KW - Gliomatosis cerebri

KW - Malignant glioma

KW - Radiation

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84883747107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883747107&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1058-x

DO - 10.1007/s11060-013-1058-x

M3 - Article

VL - 112

SP - 267

EP - 275

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -